Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker BIIB · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| May 22, 2026 | TOFIDENCE TOCILIZUMAB-BAVI | BIIB Biogen Ma | Biologic (BLA), supplement BIOSIMILAR | BLA761354 ↗ |
| Apr 20, 2026 | ZURZUVAE ZURANOLONE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA217369 ↗ |
| Apr 7, 2026 | SKYCLARYS OMAVELOXOLONE | BIIB Biogen US | New drug (NDA), supplement Labeling | NDA216718 ↗ |
| Mar 27, 2026 | SPINRAZA NUSINERSEN SODIUM | BIIB Biogen | New drug (NDA), supplement Efficacy | NDA209531 ↗ |
| Mar 18, 2025 | TYSABRI NATALIZUMAB | BIIB Biogen Idec | Biologic (BLA), supplement Labeling | BLA125104 ↗ |
| Mar 6, 2025 | TOFIDENCE TOCILIZUMAB-BAVI | BIIB Biogen Ma | Biologic (BLA), supplement Labeling | BLA761354 ↗ |
| Dec 20, 2024 | SKYCLARYS OMAVELOXOLONE | BIIB Biogen US | New drug (NDA), supplement Labeling | NDA216718 ↗ |
| Dec 20, 2024 | SKYCLARYS OMAVELOXOLONE | BIIB Biogen US | New drug (NDA), supplement Efficacy | NDA216718 ↗ |
| Dec 3, 2024 | TOFIDENCE TOCILIZUMAB-BAVI | BIIB Biogen Ma | Biologic (BLA), supplement Labeling | BLA761354 ↗ |
| Sep 11, 2024 | VUMERITY DIROXIMEL FUMARATE | BIIB Biogen | New drug (NDA), supplement Manufacturing (CMC) | NDA211855 ↗ |
| Jul 31, 2024 | ZURZUVAE ZURANOLONE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA217369 ↗ |
| Jul 22, 2024 | TOFIDENCE TOCILIZUMAB-BAVI | BIIB Biogen Ma | Biologic (BLA), supplement BIOSIMILAR | BLA761354 ↗ |
| Apr 10, 2024 | SPINRAZA NUSINERSEN SODIUM | BIIB Biogen | New drug (NDA), supplement Labeling | NDA209531 ↗ Letter or label ↗ |
| Apr 10, 2024 | SPINRAZA NUSINERSEN SODIUM | BIIB Biogen | New drug (NDA), supplement Labeling | NDA209531 ↗ Letter or label ↗ |
| Mar 22, 2024 | VUMERITY DIROXIMEL FUMARATE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA211855 ↗ |
| Mar 15, 2024 | ADUHELM ADUCANUMAB-AVWA | BIIB Biogen Inc | Biologic (BLA), supplement Manufacturing (CMC) | BLA761178 ↗ |
| Mar 12, 2024 | TECFIDERA DIMETHYL FUMARATE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA204063 ↗ |
| Jan 25, 2024 | SKYCLARYS OMAVELOXOLONE | BIIB Biogen US | New drug (NDA), supplement Labeling | NDA216718 ↗ |
| Dec 13, 2023 | VUMERITY DIROXIMEL FUMARATE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA211855 ↗ |
| Dec 13, 2023 | TECFIDERA DIMETHYL FUMARATE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA204063 ↗ |
| Oct 30, 2023 | TYSABRI NATALIZUMAB | BIIB Biogen Idec | Biologic (BLA), supplement Labeling | BLA125104 ↗ |
| Oct 25, 2023 | TYSABRI NATALIZUMAB | BIIB Biogen Idec | Biologic (BLA), supplement Labeling | BLA125104 ↗ |
| Sep 29, 2023 | TOFIDENCE TOCILIZUMAB-BAVI | BIIB Biogen Ma | Biologic (BLA) UNKNOWN | BLA761354 ↗ |
| Aug 30, 2023 | ADUHELM ADUCANUMAB-AVWA | BIIB Biogen Inc | Biologic (BLA), supplement Labeling | BLA761178 ↗ |
| Aug 24, 2023 | TYSABRI NATALIZUMAB | BIIB Biogen Idec | Biologic (BLA), supplement REMS | BLA125104 ↗ |
| Aug 4, 2023 | ZURZUVAE ZURANOLONE | BIIB Biogen | New drug (NDA) Type 1 - New Molecular Entity | NDA217369 ↗ |
| Jul 28, 2023 | PLEGRIDY PEGINTERFERON BETA-1A | BIIB Biogen Idec Inc | Biologic (BLA), supplement Labeling | BLA125499 ↗ |
| Jul 28, 2023 | AVONEX, AVONEX PEN INTERFERON BETA-1A | BIIB Biogen | Biologic (BLA), supplement Labeling | BLA103628 ↗ |
| Apr 25, 2023 | QALSODY TOFERSEN | BIIB Biogen Ma | New drug (NDA) Type 1 - New Molecular Entity | NDA215887 ↗ |
| Apr 11, 2023 | TYSABRI NATALIZUMAB | BIIB Biogen Idec | Biologic (BLA), supplement Labeling | BLA125104 ↗ |
| Apr 11, 2023 | TYSABRI NATALIZUMAB | BIIB Biogen Idec | Biologic (BLA), supplement REMS | BLA125104 ↗ |
| Feb 28, 2023 | SKYCLARYS OMAVELOXOLONE | BIIB Biogen US | New drug (NDA) Type 1 - New Molecular Entity | NDA216718 ↗ |
| Feb 17, 2023 | SPINRAZA NUSINERSEN SODIUM | BIIB Biogen | New drug (NDA), supplement Labeling | NDA209531 ↗ |
| Feb 10, 2023 | VUMERITY DIROXIMEL FUMARATE | BIIB Biogen | New drug (NDA), supplement Efficacy | NDA211855 ↗ |
| Feb 10, 2023 | TECFIDERA DIMETHYL FUMARATE | BIIB Biogen | New drug (NDA), supplement Efficacy | NDA204063 ↗ |
| Feb 8, 2023 | ADUHELM ADUCANUMAB-AVWA | BIIB Biogen Inc | Biologic (BLA), supplement Efficacy | BLA761178 ↗ |
| Nov 16, 2022 | VUMERITY DIROXIMEL FUMARATE | BIIB Biogen | New drug (NDA), supplement Manufacturing (CMC) | NDA211855 ↗ |
| Sep 29, 2022 | VUMERITY DIROXIMEL FUMARATE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA211855 ↗ |
| Sep 29, 2022 | TECFIDERA DIMETHYL FUMARATE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA204063 ↗ Letter or label ↗ |
| Sep 29, 2022 | TECFIDERA DIMETHYL FUMARATE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA204063 ↗ Letter or label ↗ |
| Apr 29, 2022 | ADUHELM ADUCANUMAB-AVWA | BIIB Biogen Inc | Biologic (BLA), supplement Labeling | BLA761178 ↗ |
| Mar 29, 2022 | PLEGRIDY PEGINTERFERON BETA-1A | BIIB Biogen Idec Inc | Biologic (BLA), supplement Labeling | BLA125499 ↗ |
| Feb 10, 2022 | VUMERITY DIROXIMEL FUMARATE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA211855 ↗ |
| Feb 10, 2022 | TECFIDERA DIMETHYL FUMARATE | BIIB Biogen | New drug (NDA), supplement Labeling | NDA204063 ↗ Letter or label ↗ |
| Dec 10, 2021 | TYSABRI NATALIZUMAB | BIIB Biogen Idec | Biologic (BLA), supplement Labeling | BLA125104 ↗ Letter or label ↗ |
| Dec 10, 2021 | TYSABRI NATALIZUMAB | BIIB Biogen Idec | Biologic (BLA), supplement Labeling | BLA125104 ↗ Letter or label ↗ |
| Nov 3, 2021 | PLEGRIDY PEGINTERFERON BETA-1A | BIIB Biogen Idec Inc | Biologic (BLA), supplement Labeling | BLA125499 ↗ |
| Nov 3, 2021 | AVONEX, AVONEX PEN INTERFERON BETA-1A | BIIB Biogen | Biologic (BLA), supplement Labeling | BLA103628 ↗ |
| Jul 7, 2021 | ADUHELM ADUCANUMAB-AVWA | BIIB Biogen Inc | Biologic (BLA), supplement Labeling | BLA761178 ↗ Letter or label ↗ |
| Jun 7, 2021 | ADUHELM ADUCANUMAB-AVWA | BIIB Biogen Inc | Biologic (BLA) Type 1 - New Molecular Entity | BLA761178 ↗ Letter or label ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates